

**Remarks**

In the Office Action, it is required that the pending claims 60-78 be restricted to one of two groups. (Office Action, page 2). Applicants provisionally elect Group I (*i.e.*, claims 60-71 drawn to O-desmethylvenlafaxine succinate and compositions).


Applicants respectfully submit, however, that a single search directed to O-desmethylvenlafaxine succinate would necessarily encompass all of the claims in Groups I and II. For this reason, it is believed that the examination of Groups I-III would not impose an unreasonable burden on the Examiner. (*See Manual of Patent Examining Procedure*, §803.01). Therefore, Applicants respectfully request that the restriction requirement be withdrawn.

In addition, it is also indicated in the Office Action that a single species election is required. However, Applicants respectfully point out that the provisionally elected claims are directed to one species, *i.e.*, O-desmethylvenlafaxine succinate. Therefore, Applicants respectfully request that the single species election requirement be withdrawn.<sup>1</sup>

No fee is believed due for this submission. If any fees are required, however, please charge such fee(s) to Jones Day Deposit Account No. 503013.

Date May 3, 2007

Respectfully submitted,

  
Hoon Choi

**Jones Day**

L0209

Ltd. Recog. No.

For: Anthony M. Insogna (Reg. No. 35,203)  
**Jones Day**  
12265 El Camino Real, Suite 200  
San Diego, CA 92130  
(858) 314-1200

<sup>1</sup> Nevertheless, for avoidance of any doubt, Applicants also provisionally elect O-desmethylvenlafaxine succinate.